WuXi Biologics to Open Clinical Mfg. Facility in Cranbury, NJ

WuXi Biologics has signed a 10-year lease for a clinical manufacturing facility (MFG18) in Cranbury, NJ.

The new facility will install total 6000 L bioreactors, Process Development (PD), Quality Control (QC) labs, along with supporting functions. The 66,000-sq.-ft. facility is expected to become operational in late 2020 and will add as many as 100 jobs to the region.

WuXi Biologics' also recently purchased land to build a new 107,000-sq.-ft. clinical and commercial manufacturing facility in Worcester, MA, and leased a 33,000-sq.-ft. site to establish a process development lab in King of Prussia, PA.

"We are excited to announce our third site in the United States and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries, and we look forward to working with and serving our partners in the area to benefit patients worldwide," said Dr. Chris Chen, CEO of WuXi Biologics.